Converging computational and laboratory technologies are helping anti-cancer immune responses hit their target more effectively.

With a rising measles outbreak in the U.S., experts stress the importance of vaccination. While most individuals are ...

The Food and Drug Administration (FDA) has approved Uplizna ® (inebilizumab-cdon) for the treatment of immunoglobulin G4-related disease (IgG4-RD) in adult patients.

After dropping the FNAIT therapy, Rallybio will prioritise another candidate that is being investigated in complement-driven diseases.

Johnson & Johnson reports long-term efficacy and steroid-sparing benefits of nipocalimab in antibody-positive generalized ...

J&J exhibited additional findings from the Vivacity-MG3 study, displaying that nipocalimab met its key secondary endpoint.

Epsilogen has acquired antibody developer TigaTx in a deal that collates work from the companies’ alternative antibody ...

MG-ADL (Myasthenia Gravis - Activities of Daily Living) provides a rapid clinical assessment of the patient's recall of symptoms impacting activities of daily living, with a total score range of 0 to ...

Johnson & Johnson announced results from additional analyses of the Phase 3 Vivacity-MG3 double-blind study and the ongoing open-label ...

The combined company will clinically advance Epsilogen's MOv18 IgE antibody in ovarian cancer and TigaTx's anti-EGFR IgA antibody.

U.K.-based Epsilogen has bought Boston biotech TigaTx with the aim of creating “the world’s leading pan-isotype cancer ...

High-speed atomic force m (HS-AFM) reveals nanoscale differences in small extracellular vesicles (sEVs), improving biomarker ...